Objective:

To elucidate the links between HERV expression and tumor immunogenicity in different biological subtypes of early breast cancer (eBC).

Approach:

Key Findings:

• Overall HERV tumor load varies little among different eBC subtypes and does not impact tumor immunogenicity.
• A signature of 19 HERVs associated with viral mimicry was identified, termed 'Breast HERV19'.
• 'Breast HERV19' expression is linked to better prognosis in HR+HER2− eBC.
• Expression of 'Breast HERV19' correlates with biomarkers of sensitivity to anti PD-1 immunotherapy.

Interpretation:

Limitations:

• The study relies on publicly available data, which may limit the generalizability of findings.
• Further validation in clinical settings is necessary to confirm the utility of the 'Breast HERV19' signature.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.